Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19120757 | 0.81 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL1571975 | 0.81 | TSHR (0.52) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15003 | 0.81 | TSHR (0.52) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| Ammonia Solution, Strong SCHEMBL21518155 | 0.79 | TSHR (0.50) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| Lithium SCHEMBL9504699 | 0.79 | TSHR (0.50) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9504704 | 0.79 | TSHR (0.50) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30556103 | 0.78 | TSHR (0.44) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11763588 | 0.78 | TSHR (0.44) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL23639417 | 0.78 | IDO1 (0.56) | IDO1CYP2D6ALDH1A1TAAR1MAOA | |
| SCHEMBL3701482 | 0.77 | TSHR (0.48) | TSHRIDO1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021049472-A1 | COMPOUND, RESIN, COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, UNDERLAYER FILM, AND OPTICAL ARTICLE | 学校法人 関西大学 | 2021-03-18 | — | — | WO | disclosed |
| US-10807951-B2 | mTORC1 modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-20 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190112268-A1 | mTORC1 MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-18 | — | — | US | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-0899265-B1 | Triazole derivatives and their use as antimycotic agents | SSP CO LTD (JP) | 2003-01-29 | — | — | EP | disclosed |
| EP-0814079-B1 | Triazole derivative or salt thereof | SS PHARMACEUTICAL CO (JP) | 2001-03-28 | — | — | EP | disclosed |
| US-6063945-A | FUNGICIDES | SS PHARMACEUTICAL CO., LTD. (JP) | 2000-05-16 | — | — | US | disclosed |
| US-6008239-A | FUNGICIDES FOR THE PREVENTION AND TREATMENT OF MAMMALIAN MYCOTIC INFECTIONS | SSP CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| US-5939448-A | ANTIMYCOTIC AGENT | SS PHARMACEUTICAL CO., LTD. (JP) | 1999-08-17 | — | — | US | disclosed |
| EP-0899265-A1 | Triazole derivatives and their use as antimycotic agents | SSP Co., Ltd. (JP) | 1999-03-03 | — | — | EP | disclosed |
| EP-0814079-A1 | Triazole derivative or salt thereof | SS PHARMACEUTICAL CO., LTD. (JP) | 1997-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA1 4843/4885CA2 1067/4885 |
| US-20190112268-A1 | mTORC1 MODULATORS | MTOR, RPTOR, RICTOR | TSHR 3686/4885CA1 4829/4885CA2 4415/4885 |
| US-10807951-B2 | mTORC1 modulators | MTOR, RPTOR, RICTOR | TSHR 3686/4885CA1 4829/4885CA2 4415/4885 |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA1 4843/4885CA2 1067/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA1 4843/4885CA2 1067/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA1 4843/4885CA2 1067/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA1 4843/4885CA2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.